BioSpace News Archive

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, announced a partnership with Rady Children’s Institute for Genomic Medicine to advance and evaluate a novel newborn screening technology to facilitate diagnosis of genetic diseases.

Presentation by Pionyr Chief Medical Officer Leonard Reyno, M.D., features leading research in modulating innate immunity to treat cancer.

In pre-clinical models of trastuzumab resistant MUC4 HER2+ breast cancer, treatment with INB03™ decreases MUC4 expression, reverses resistance to trastuzumab based therapies, and promotes an immunologically active TME.

CytomX Therapeutics, Inc. announced that on June 15, 2022, the Company granted two new employees options to purchase a total of 109,000 shares of the Company’s common stock at an exercise price per share equal to $1.72, which was the closing trading price on June 15, 2022, the date of the grant.

Cizzle Biotechnology Holdings PLC, the UK based diagnostics developer, is pleased to announce that it has entered into an agreement with the Behnke Group, a Texas -based healthcare consulting firm with decades of experience collaborating with healthcare organizations across the USA and internationally.

Avid Bioservices, Inc., a dedicated contract development and manufacturing organization focused on development and CGMP manufacturing services for biotechnology and pharmaceutical companies, highlighted the companies’ collaborative efforts that enabled the phase-one opening of its new purpose-built, 53,000-square-foot viral vector and CGMP facility in Costa Mesa, California, in only eight months.

LUMINELLE (UVision360, Inc.), an innovative FEMTECH/ medical device company, announces today new additions to their Board of Directors.

Pear Therapeutics to Participate in the Cowen 7th Annual FutureHealth Conference.

Edgewise Therapeutics, Inc. announced that new 2-month interim data from the ARCH open label study of EDG-5506 in individuals with BMD will be presented at the 2022 New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 20-23, 2022.

Facility to Provide Clinical Supply of Lead Gene Therapy Programs TN-201 and TN-401 for Planned First-in-Human Studies.